Objective To investigate comparative analysis of PKP and conservative treatment for old osteoporotic vertebral compression fractures ,to provide a reference for clinical treatment .Methods From January 2011 to March 2014 48 cases of OVCF patients were selected ,they were divided into two groups according to treatment which were observation group (26 cases) and con‐trol group (22 patients) ,control group with the implementation of conservative treatment ,observation group was implemented with surgical treatment for patients with PKP .Two groups of patients before and after treatment quality of life scores (SF‐36) ,pain vis‐ual analogue scale (VAS) ,Oswestry Disability Index and radiographic findings were compared .Results The observation group and the control group before and after treatment VAS scores were significantly different (F= 84 .393 ,P= 0 .019 ;F= 61 .388 ,P=0 .028);VAS score in observation group after treatment 1d ,6 months were significantly lower than the control group ,the difference was statistically significant (t= -18 .843 ,P=0 .000;t= -17 .174 ,P=0 .000);SF‐36 scores in the observation group was 85 .18 ± 8 .01 ,significantly higher than 74 .29 ± 6 .93 ,the difference was statistically significant (t=8 .569 ,P=0 .006);in observation group after treatment Oswestry disability scores compared with the control group ,the difference was statistically significant (t=6 .217 , P=0 .010);in the observation group after 1 d ,6 months the middle of vertebral height was (19 .72 ± 2 .44) mm ,(19 .70 ± 2 .17) mm ,were higher than before treatment ,the difference was statistically significant (F=23 .221 ,P=0 .028) .Conclusion PKP can improve pain and quality of life for patients ,which is worthy of clinical application .

Objective:To explore the clinical application and long-term safety of hydroxychloroquine sulfate (HCQ) in the treatment of rheumatic diseases.Methods:A multi-center cross-sectional study was conducted between August 2017 and August 2018 in a random sample of eleven medical institutions of rheumatology and immunology in China. Patients who took HCQ for more than 3 months were enrolled into this study. The cumulative dose and long-term side effects of HCQ were recorded. The changes of laboratory indexes before and after treatment with HCQ were analyzed. Categorical variables were presented with counts and proportions, and evaluated by Chi-square test. Continuous parametric data were presented as Mean±standard deviation, and evaluated by Student's t test or Mann-Whitney U test. P-values less than 0.05 were considered statistically significant. Results:A total of 886 patients with rheumatic diseases were enrolled into this study, including 505 cases with systemic lupus erythematosus (57.0%), 210 cases with rheumatoid arthritis (23.7%), 80 cases with Sj?gren's syndrome (9.0%), 57 cases with undifferentiated connective tissue disease (6.4%), 12 cases of systemic vasculitis (1.4%), 10 cases of mixed connective tissue disease (1.1%), 7 cases of myositis (0.8%) and 5 cases with systemic sclerosis (0.6%). The most common long-term side effects of HCQ was skin or mucous lesions (12.4%) and vision problems (8.0%). Other adverse reactions included problems of digestive system (3.0%), nervous system (2.1%), musculoskeletal system (1.1%) and cardiovascular system (0.9%). 140 cases (15.8%) had stopped taking HCQ during the treatment. More than half of them decided to stop taking medicine by themselves. Fifty-four patients (6.1%) stopped using HCQ due to side effects while 24 of them took it again, and another 12 patients (1.4%) stopped the drug due to remission of illness. Patients were divided into three groups according to the cumulative dose of HCQ: less than 500 g, 500-1 000 g and more than 1 000 g respectively. There was significant difference in the incidence of long-term side effects among the three groups ( χ2=6.382, P=0.041). The last group (more than 1 000 g) suffered the highest incidence of long-term adverse reactions (37.1%). No severe adverse drug reactions were observed in this study. Conclusion:Hydroxychloroquine is widely used in the treatment of rheumatic diseases. The incidence of long-term side effects is 20.4%, is 6.1% lead to drug withdrawal, which are especially related to the cumulative doses. It should be adjusted properly according to the clinical application.